These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36368286)

  • 1. Paclitaxel resistance related to nuclear envelope structural sturdiness.
    Smith ER; Wang JQ; Yang DH; Xu XX
    Drug Resist Updat; 2022 Dec; 65():100881. PubMed ID: 36368286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Lamin A/C Expression Is a Key Determinant of Paclitaxel Sensitivity.
    Smith ER; Leal J; Amaya C; Li B; Xu XX
    Mol Cell Biol; 2021 Jun; 41(7):e0064820. PubMed ID: 33972393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel.
    Smith ER; Xu XX
    J Cancer Biol; 2021; 2(4):86-93. PubMed ID: 35048083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Kelland LR; Abel G
    Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel and docetaxel in prostate cancer.
    Obasaju C; Hudes GR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemistry and chemical biology of taxane anticancer agents.
    Miller ML; Ojima I
    Chem Rec; 2001; 1(3):195-211. PubMed ID: 11895119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
    Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
    Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
    Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
    Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
    Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.
    Smith ER; Huang M; Schlumbrecht MP; George SHL; Xu XX
    Front Oncol; 2022; 12():907520. PubMed ID: 36185294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
    Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G
    Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
    Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
    BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
    Fitzpatrick FA; Wheeler R
    Int Immunopharmacol; 2003 Dec; 3(13-14):1699-714. PubMed ID: 14636822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
    Fumoleau P; Perrocheau G; Maugard-Louboutin C; Lemevel B
    Bull Cancer; 1995 Aug; 82(8):629-36. PubMed ID: 7492819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.
    Kenicer J; Spears M; Lyttle N; Taylor KJ; Liao L; Cunningham CA; Lambros M; MacKay A; Yao C; Reis-Filho J; Bartlett JM
    BMC Cancer; 2014 Oct; 14():762. PubMed ID: 25312014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The scientific rationale for developing taxoids.
    Aapro M
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
    Grant DS; Williams TL; Zahaczewsky M; Dicker AP
    Int J Cancer; 2003 Mar; 104(1):121-9. PubMed ID: 12532428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.